These direct and indirect effects of resistin may work in synergy in the breast tumor microenvironment, and therefore targeting the direct pathway of resistin, or its indirect pathway, such as CXCL5 reported in this study, may be equally important for future development of therapeutic intervention in the breast cancer associated with elevated expression of resistin. The gene discussed is CXCL5; the disease is breast neoplasm.